



(51) International Patent Classification:

A61K 9/51 (2006.01) A61K 9/00 (2006.01)
A61K 47/24 (2006.01) A61K 9/12 (2006.01)
A61K 48/00 (2006.01) C07K 14/435 (2006.01)

(21) International Application Number:

PCT/US2022/021437

(22) International Filing Date:

22 March 2022 (22.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/164,522 22 March 2021 (22.03.2021) US
63/164,577 23 March 2021 (23.03.2021) US
63/229,495 04 August 2021 (04.08.2021) US

(71) Applicant: **RECODE THERAPEUTICS, INC.** [US/US];
1455 Adams Drive, Menlo Park, California 94025 (US).

(72) Inventors: **KHARITONOV, Vladimir**; c/o ReCode Therapeutics, Inc., 1455 Adams Drive, Menlo Park, California 94025 (US). **WUSTMAN, Brandon**; c/o ReCode Therapeutics, Inc., 1455 Adams Drive, Menlo Park, California 94025 (US).

apeutics, Inc., 1455 Adams Drive, Menlo Park, California 94025 (US). **EBY, Jackson**; c/o ReCode Therapeutics, Inc., 1455 Adams Drive, Menlo Park, California 94025 (US). **BHATTACHARJEE, Rumpa**; c/o ReCode Therapeutics, Inc., 1455 Adams Drive, Menlo Park, California 94025 (US). **ISHIMARU, Daniella**; c/o ReCode Therapeutics, Inc., 1455 Adams Drive, Menlo Park, California 94025 (US). **HENNIG, Mirko**; c/o ReCode Therapeutics, Inc., 1455 Adams Drive, Menlo Park, California 94025 (US).

(74) Agent: **LIN, Yinan**; WILSON SONSINI GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,

(54) Title: POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS, AND METHODS OF USE THEREOF




Fig. 30C

(57) Abstract: Compositions of polynucleotide(s) are disclosed. A polynucleotide may encode for a polypeptide, protein, or functional fragment thereof associated with primary ciliary dyskinesia (PCD), such as dynein axonemal intermediate chain 1 (DNAI1). Pharmaceutical compositions, kits, and methods for treating a disease or condition associated with cilia maintenance and function, and impaired function of the axoneme are also disclosed. The polynucleotide may be assembled with a lipid composition for delivery to an organ, such as the lung, of a subject. The lipid composition may comprise an ionizable cationic lipid. The polynucleotide can be expressed within cells of the organ of the subject.

[Continued on next page]

RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*